Roche gets US antitrust clearance for 89bio deal; intends to close Thursday
By Flavia Fortes ( October 30, 2025, 09:39 GMT | Insight) -- Roche said Thursday that it will close its $3.5 billion acquisition of liver drug developer 89bio. The announcement indicates that the companies have received clearance from the US antitrust authorities, which had until Wednesday to request additional information about the deal. Roche said Thursday that it will close its $3.5 billion acquisition of liver drug developer 89bio....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.